Success Metrics

Clinical Success Rate
37.5%

Based on 3 completed trials

Completion Rate
38%(3/8)
Active Trials
3(13%)
Results Posted
133%(4 trials)
Terminated
5(21%)

Phase Distribution

Ph phase_1
4
17%
Ph early_phase_1
2
8%
Ph phase_2
2
8%
Ph not_applicable
13
54%

Phase Distribution

6

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution21 total trials
Early Phase 1First-in-human
2(9.5%)
Phase 1Safety & dosage
4(19.0%)
Phase 2Efficacy & side effects
2(9.5%)
N/ANon-phased studies
13(61.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

30.0%

3 of 10 finished

Non-Completion Rate

70.0%

7 ended early

Currently Active

3

trials recruiting

Total Trials

24

all time

Status Distribution
Active(4)
Completed(3)
Terminated(7)
Other(10)

Detailed Status

unknown10
Terminated5
Completed3
Recruiting3
Withdrawn2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
3
Success Rate
37.5%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (9.5%)
Phase 14 (19.0%)
Phase 22 (9.5%)
N/A13 (61.9%)

Trials by Status

completed313%
withdrawn28%
recruiting313%
unknown1042%
not_yet_recruiting14%
terminated521%

Recent Activity

3 active trials
Showing 5 of 24
not_yet_recruitingearly_phase_1

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

NCT07781852
recruitingphase_1

Positron Emission Tomography (PET) Imaging of Thrombosis

NCT03830320
recruiting

Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

NCT06092125
withdrawnphase_2

Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT

NCT04271436
recruitingphase_1

Imaging Synapses With [11C] UCB-J in the Human Brain

NCT04038840
View all 24 trials

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT07781852Early Phase 1

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

Not Yet Recruiting
NCT03830320Phase 1

Positron Emission Tomography (PET) Imaging of Thrombosis

Recruiting
NCT06092125

Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

Recruiting
NCT04271436Phase 2

Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT

Withdrawn
NCT04038840Phase 1

Imaging Synapses With [11C] UCB-J in the Human Brain

Recruiting
NCT04311619Phase 1

Does rTMS Induce Synaptic Plasticity?

Withdrawn
NCT03804424Early Phase 1

64Cu-LLP2A for Imaging Multiple Myeloma

Terminated
NCT04271254Not Applicable

PET/MR Characterization of Renal Cell Carcinomas

Terminated
NCT05003830

Application of Multi-probe PET/MR Imaging in the Diagnosis and Evaluation of Alzheimer's Disease

Unknown
NCT05006326Not Applicable

Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma

Unknown
NCT04605939Not Applicable

Clinical Application of Fibroblast Activation Protein PET/MRI in Liver Fibrosis

Unknown
NCT04554719Not Applicable

Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Malignant Tumors

Unknown
NCT03739281Not Applicable

PET/MR Imaging in Lung Cancer

Terminated
NCT05466760

PET/MR Radiomics for Breast Cancer Diagnosis

Unknown
NCT04332419Not Applicable

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

Completed
NCT04552847Phase 2

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Completed
NCT03076333Not Applicable

PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas

Completed
NCT04149353Not Applicable

PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo

Terminated
NCT04159376Not Applicable

Assessment of the Accuracy of PET/MR in Detection and Monitoring Response of Bone Metastases

Unknown
NCT04154254Not Applicable

Applying PET/MR for Dementia Applications

Unknown

Drug Details

Intervention Type
DEVICE
Total Trials
24